4.5 Article

Disturbed sleep in bipolar disorder is related to an elevation of IL-6 in peripheral monocytes

Journal

MEDICAL HYPOTHESES
Volume 81, Issue 6, Pages 1031-1033

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.mehy.2013.09.025

Keywords

-

Funding

  1. GlaxoSmithKline
  2. AstraZeneca
  3. AstraZeneca und Lilly

Ask authors/readers for more resources

Bipolar disorder is a severe psychiatric disorder that is associated with persistent changes in the quality, duration and architecture of sleep. Currently there is no unifying hypothesis explaining the alterations in sleep observable in patients with bipolar disorder and management is often difficult though vital. Sleep is modified by various cytokines including IL-6. Elevated levels of IL-6 are associated with a poorer quality of sleep and changes in the architecture of sleep similar to those observed in bipolar disorder. Therapeutic administration of Interferon causes elevations of intrathecal IL-6 concentrations and appears to provoke a deteriorating quality of sleep. The blockade of IL-6 with tocilizumab in rheumatoid arthritis is associated with improvements in the quality of sleep. Bipolar disorder is associated with elevated levels of IL-6 and in particular elevated levels of mRNA coding for IL-6 in peripheral monocytes. We propose that the changes observed in the sleep of patients with bipolar disorder are related to the elevation of IL-6 and that this correlates with an elevated expression of mRNA coding for IL-6 expression in peripheral monocytes. (C) 2013 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Pharmacology & Pharmacy

Ketamine in the Treatment of Depressive Episodes

Philipp Ritter, Hannelore Findeis, Michael Bauer

PHARMACOPSYCHIATRY (2020)

Review Health Care Sciences & Services

Healthcare system performance in continuity of care for patients with severe mental illness: A comparison of five European countries

Pablo Nicaise, Domenico Giacco, Bettina Soltmann, Andrea Pfennig, Elisabetta Miglietta, Antonio Lasalvia, Marta Welbel, Jacek Wciorka, Victoria Jane Bird, Stefan Priebe, Vincent Lorant

HEALTH POLICY (2020)

Article Clinical Neurology

Efficacy of cognitive-behavioral group therapy in patients at risk for serious mental illness presenting with subthreshold bipolar symptoms: Results from a prespecified interim analysis of a multicenter, randomized, controlled study

Karolina Leopold, Michael Bauer, Andreas Bechdolf, Christoph U. Correll, Martin Holtmann, Georg Juckel, Martin Lambert, Thomas D. Meyer, Steffi Pfeiffer, Sarah Kittel-Schneider, Andreas Reif, Thomas J. Stamm, Maren Rottmann-Wolf, Josephine Mathiebe, Eva L. Kellmann, Philipp Ritter, Seza Kruger-Ozgurdal, Anne Karow, Lene-Marie Sondergeld, Veit Roessner, Cathrin Sauer, Andrea Pfennig

BIPOLAR DISORDERS (2020)

Article Neurosciences

Melatonin suppression by melanopsin-weighted light in patients with bipolar I disorder compared to healthy controls

Philipp Ritter, Falk Wieland, Debra J. Skene, Andrea Pfennig, Maria Weiss, Michael Bauer, Emanuel Severus, Henry Gueldner, Cathrin Sauer, Bettina Soltmann, Stefanie Neumann

JOURNAL OF PSYCHIATRY & NEUROSCIENCE (2020)

Article Clinical Neurology

A review of the update of the German S3-guideline on diagnostics and therapy of bipolar disorders 2019

A. Pfennig, B. Soltmann, P. Ritter, T. Bschor, M. Hautzinger, T. D. Meyer, F. Padberg, P. Brieger, M. Schaefer, C. U. Correll, M. Bauer

NERVENARZT (2020)

Review Clinical Neurology

Measuring circadian function in bipolar disorders: Empirical and conceptual review of physiological, actigraphic, and self-report approaches

Greg Murray, John Gottlieb, Maria Paz Hidalgo, Bruno Etain, Philipp Ritter, Debra J. Skene, Corrado Garbazza, Ben Bullock, Kathleen Merikangas, Vadim Zipunnikov, Haochang Shou, Robert Gonzalez, Jan Scott, Pierre A. Geoffroy, Benicio N. Frey

BIPOLAR DISORDERS (2020)

Article Clinical Neurology

Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action

Mirko Manchia, Eduard Vieta, Olav B. Smeland, Cara Altimus, Andreas Bechdolf, Frank Bellivier, Veerle Bergink, Andrea Fagiolini, John R. Geddes, Tomas Hajek, Chantal Henry, Ralph Kupka, Trine Lagerberg, Rasmus W. Licht, Monica Martinez-Cengotitabengoa, Gunnar Morken, Rene E. Nielsen, Ana Gonzalez Pinto, Andreas Reif, Marcella Rietschel, Phillip Ritter, Thomas G. Schulze, Jan Scott, Emanuel Severus, Aysegul Yildiz, Lars Vedel Kessing, Michael Bauer, Guy M. Goodwin, Ole A. Andreassen

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2020)

Article Clinical Neurology

Association of pro-inflammatory cytokines with clinical features in euthymic patients with Bipolar-I-Disorder

Edgar Arrua Vares, Sarah Lehmann, Cathrin Sauer, Carmine Pariante, Falk Wieland, Bettina Soltmann, Michael Bauer, Philipp Ritter

JOURNAL OF AFFECTIVE DISORDERS (2020)

Article Neurosciences

Urothelial toxicity of esketamine in the treatment of depression

Hannelore Findeis, Cathrin Sauer, Anthony Cleare, Michael Bauer, Philipp Ritter

PSYCHOPHARMACOLOGY (2020)

Article Psychiatry

Social contacts, friends and satisfaction with friendships in patients with psychotic, mood and neurotic disorders 1 year after hospitalisation: data from five European countries

Kurt Buhagiar, Stefan Priebe, Justyna Klingemann, Antonio Lasalvia, Pablo Nicaise, Bettina Soltmann, Domenico Giacco

Summary: Objective and subjective social relationship indicators were weakly correlated concepts among patients with severe mental illness. While patients with psychotic disorders initially reported less social contact with friends, this difference disappeared when confounders were taken into account, suggesting that interventions targeting social relationships do not necessitate diagnosis-specific adaptations.

SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY (2021)

Article Clinical Neurology

Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study

Vera M. Ludwig, Cathrin Sauer, Allan H. Young, James Rucker, Michael Bauer, Hannelore Findeis, Philipp Ritter

Summary: The study evaluated changes in blood pressure and heart rate during esketamine administration in patients with and without concomitant tranylcypromine treatment. Results showed that while there were statistically significant increases in blood pressure for patients receiving tranylcypromine, these changes were clinically insignificant. The study suggests that combining esketamine and tranylcypromine at standard doses is safe, but caution should be taken with higher doses of tranylcypromine.

CNS DRUGS (2021)

Article Psychiatry

Multiperspective and Multimethod Evaluation of Flexible and Integrative Psychiatric Care Models in Germany: Study Protocol of a Prospective, Controlled Multicenter Observational Study (PsychCare)

Bettina Soltmann, Anne Neumann, Stefanie March, Ines Weinhold, Dennis Haeckl, Roman Kliemt, Fabian Baum, Marcel Romanos, Julian Schwarz, Sebastian von Peter, Yuriy Ignatyev, Katrin Arnold, Enno Swart, Martin Heinze, Jochen Schmitt, Andrea Pfennig

Summary: Germany has initiated new cross-sectoral mental health care models, including FIT64b projects, to improve the quality of hospital-based mental health care. The PsychCare study combines quantitative and qualitative data to evaluate and develop quality indicators for modern, flexible, and integrated care.

FRONTIERS IN PSYCHIATRY (2021)

Article Clinical Neurology

Practical aspects of ketamine treatment-Safety, combination treatment and comorbidities

H. Findeis, V Ludwig, P. Mikolas, J. Graff, M. Bauer, Philipp Ritter

Summary: Ketamine appears to be a safe and effective option for the treatment of unipolar and bipolar depression, with a dose of 0.5 mg/kg of S-ketamine three times per week showing effectiveness. Treatment appears to be safe regarding urotoxic side effects, combination treatment with tranylcypromine, and comorbid posttraumatic stress disorder.

NERVENARZT (2022)

Article Neurosciences

Machine Learning Prediction of Estimated Risk for Bipolar Disorders Using Hippocampal Subfield and Amygdala Nuclei Volumes

Fabian Huth, Leonardo Tozzi, Michael Marxen, Philipp Riedel, Kyra Broeckel, Julia Martini, Christina Berndt, Cathrin Sauer, Christoph Vogelbacher, Andreas Jansen, Tilo Kircher, Irina Falkenberg, Florian Thomas-Odenthal, Martin Lambert, Vivien Kraft, Gregor Leicht, Christoph Mulert, Andreas J. Fallgatter, Thomas Ethofer, Anne Rau, Karolina Leopold, Andreas Bechdolf, Andreas Reif, Silke Matura, Silvia Biere, Felix Bermpohl, Jana Fiebig, Thomas Stamm, Christoph U. Correll, Georg Juckel, Vera Flasbeck, Philipp Ritter, Michael Bauer, Andrea Pfennig, Pavol Mikolas

Summary: The pathophysiology of bipolar disorder (BD) is unclear, but a valid biomarker is needed for early detection. This study used structural MRI to compare volumes of hippocampus, amygdala, and their subfields/nuclei in individuals at risk for BD. Although there were no volume differences between risk groups, machine learning could still predict the risk for BD based on certain criteria. This suggests that neural changes may have prognostic value in BD.

BRAIN SCIENCES (2023)

Article Neurosciences

Supersensitivity of Patients With Bipolar I Disorder to Light-Induced Phase Delay by Narrow Bandwidth Blue Light

Philipp Ritter, Bettina Soltmann, Cathrin Sauer, Abdulbaki Yakac, Lynn Boekstaegers, Mirjam Reichard, Konstanze Koenitz, Michael Bauer, Henry Gueldner, Stefanie Neumann, Falk Wieland, Debra J. Skene

Summary: This study found that patients with bipolar I disorder are more prone to experiencing phase delays following exposure to blue light in the evening compared to healthy control subjects. The enhanced phase delay in bipolar disorder patients may contribute to their observed phase instability and vulnerability to forced phase shifts.

BIOLOGICAL PSYCHIATRY: GLOBAL OPEN SCIENCE (2022)

Article Medicine, Research & Experimental

Alleviating morphine-induced itching while sustaining its analgesic efficacy: Esketamine as a potential co-administrating choice

Tong Cheng, Zhusheng Chen, Yibin Qin, Xiang Zhu, Hongsheng Chen, Zhongling Xu, Xiaqing Ma

Summary: Morphine is commonly used and effective for pain relief, but its side effect of itching limits its clinical use. This paper discusses the potential of using esketamine to treat morphine-induced itching.

MEDICAL HYPOTHESES (2024)

Article Medicine, Research & Experimental

Hyperbaric oxygen therapy as a possible therapeutic candidate for sepsis-associated encephalopathy: A novel hypothesis

Sung Eun Lee, Eunjung Park, Ji-yun Kim, HyukHoon Kim

Summary: Hyperbaric oxygen therapy (HBOT) is a potential therapeutic modality that has been recognized for its favorable mechanisms in various diseases, including sepsis-associated encephalopathy (SAE). HBOT has neuroprotective effects through its anti-inflammatory and antiapoptotic effects as well as increased tissue oxygenation capacity. However, there are caveats and limitations in applying HBOT in sepsis.

MEDICAL HYPOTHESES (2024)